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Background:  The effectiveness of clopidogrel is influenced by cytochrome P450 (CYP) 2C19*2 polymorphism and concomitant use of proton 
pump inhibitors (PPIs). Despite the past study suggested that PPIs decreased the inhibition of platelet function by clopidogrel, its contribution to 
lesion outcome is unclear.
Methods:  This study included 118 Japanese patients who received clopidogrel and underwent follow-up optical coherence tomography (OCT) 
after DES implantation. The patients were divided into four groups: those had at least one CYP2C19*2 allele (*2carriers) with PPIs and without PPIs, 
those were non-carriers with PPIs and without PPIs. The incidence of intra-stent thrombus detected by OCT was compared among four groups. The 
frequencies of major adverse cardiac event (MACE), including death, myocardial infarction and target lesion revascularization were compared among 
four groups.
Results:  In non-carriers, the patients with PPIs were 50.0%. The frequency of intra-stent thrombus was not different between those with PPIs and 
without PPIs (18.2% vs. 24.2%). In *2 carriers, the patients with PPIs were 43.8%. The frequency of intra-stent thrombus was not different between 
two groups (54.8% vs. 57.1%). The frequency of MACE was not different among four groups.
Conclusions:  Our study found that the use of PPIs doesn’t affect on the incidence of intra-stent thrombus and MACE among Japanese patients 
receiving clopidogrel, regardless of CYP2C19*2 polymorphism. 
